Cell Bound Her2
Cell Bound Her2 - Related Videos
10:21
Protocol for HER2 FISH Using a Non-cross-linking, Formalin-free Tissue Fixative to Combine Advantages of Cryo-preservation and Formalin Fixation
0 Views •
Cited by 3 •
2017
Fluorescence in-situ hybridization (FISH) is often required in combination with histopathology and molecular diagnostics for selection of therapy in personalized medicine. A novel non-cross-linking, formalin-free tissue fixative that allows high quality morphologic, molecular and FISH analyses from the same specimen by addition of a post-fixation step before FISH is presented.
02:30
Isolation of Small Regulatory RNA–Bound Bacterial Target RNA Using Affinity Purification
0 Views •
2025
Source: Mercier, N., et. al., MS2-Affinity Purification Coupled with RNA Sequencing in Gram-Positive Bacteria. J. Vis. Exp. (2021)This video demonstrates the isolation of MS2-tagged small regulatory RNA (sRNA) bound to its bacterial target RNA using affinity purification with a maltose-binding protein (MBP)–MS2 coat protein fusion immobilized on amylose resin.
09:14
Examination of Proteins Bound to Nascent DNA in Mammalian Cells Using BrdU-ChIP-Slot-Western Technique
0 Views •
Cited by 4 •
2016
In this protocol, we describe a novel BrdU-ChIP-Slot-Western technique to examine proteins and histone modifications associated with newly synthesized or nascent DNA.
09:42
Using SecM Arrest Sequence as a Tool to Isolate Ribosome Bound Polypeptides
0 Views •
Cited by 6 •
2012
We describe here a technique that is now routinely used to isolate stably bound ribosome nascent chain complexes (RNCs). This technique takes advantage of the discovery that a 17 amino acid long SecM "arrest sequence" can halt translation elongation in a prokaryotic (E. coli) system, when inserted into (or fused to the C-terminus) of virtually any protein.
11:52
Analysis of Targeted Viral Protein Nanoparticles Delivered to HER2+ Tumors
0 Views •
Cited by 1 •
2013
This article details the procedures for optical imaging analysis of the tumor-targeted nanoparticle, HerDox. In particular, detailed use of the multimode imaging device for detecting tumor targeting and assessing tumor penetration is described here.
FAQs
When HER2 forms dimers with itself or other ERBB receptors without requiring ligand binding, receptor proximity enables activation of the intracellular kinase domain. The kinase then phosphorylates signaling proteins, creating molecular signals that promote cell proliferation and survival. This mechanism helps explain why increased HER2 at the membrane can alter tumor behavior even when external growth-factor stimulation is limited.
Phosphorylation acts as a molecular switch that transmits information from the activated HER2 kinase domain to downstream signaling pathways. These pathways can increase proliferation and reduce susceptibility to cell death. In cancer research, examining this signaling output alongside receptor abundance helps distinguish the presence of cell-bound HER2 from its functional activity within tumor cells.
The amount of HER2 at the cell membrane and its localization provide complementary information about receptor status. Abundance indicates how much target is available, whereas localization shows whether the receptor is positioned where signaling can occur. Evaluating both features can improve tumor classification and biomarker development by connecting receptor distribution with potential signaling behavior and treatment relevance.
These treatment strategies address different levels of the HER2 system. Antibody-based approaches target the receptor through its extracellular, cell-associated presence, while kinase inhibitors act on intracellular enzymatic signaling. Comparing these strategies in studies of cell-bound HER2 can help researchers examine how receptor targeting and signal inhibition relate to therapeutic response or resistance.
Researchers should consider both receptor abundance and membrane localization rather than treating HER2 as a single numerical feature. These measurements can support tumor classification and biomarker development, while signaling assessment adds information about receptor activity. Together, the results help relate the observed HER2 status to possible eligibility for targeted treatment strategies and to variation among tumor samples.
Measurement of membrane-associated HER2 can provide evidence for whether a tumor contains the receptor targeted by antibody-based or kinase-inhibitor strategies. The result is most informative when interpreted with localization and signaling information, because receptor presence alone may not describe functional behavior. In cancer research, this integrated view supports treatment selection and investigation of differing therapeutic responses.
Studying cell-bound HER2 can help connect therapeutic resistance with changes in receptor abundance, localization, or signaling. If treatment response differs despite measurable HER2, researchers can compare these features to determine whether altered receptor behavior may contribute. Such analyses support biomarker development and clarify why tumors with related HER2 status can show different outcomes during targeted treatment studies.